Latest news with #Maz
Time of India
5 days ago
- Politics
- Time of India
Ex-BJP MP Gopal Shetty among 2 acquitted by Mumbai court in 20-year-old police assault case as witness turns hostile
Mumbai: With the purported victim claiming that the push might have been unintentional due to the accused being in a hurry, a sessions court recently acquitted former BJP MP Gopal Shetty (71) and party functionary Ganesh Khankar (52) over two decades after they were accused of storming into a police station and attacking a constable. Tired of too many ads? go ad free now It was alleged that their reaction came after Kasturba Marg police booked Netaji Shinde, a BJP worker from Borivli (E), under the Maharashtra Prevention of Dangerous Activities (MPDA) Act. The constable turned hostile in court and did not support the prosecution's case. "From overall evidence on record, it appears that both accused visited Kasturba Marg police station at midnight, possibly with the intention of assisting or supporting their party activist, Netaji Shinde, who was detained under the MPDA Act," additional sessions judge Satyanarayan R Navander said. He added that the only witness who partly supported the prosecution case was the constable, and even his testimony was contradictory, vague, and substantially weakened during cross-examination. "No independent or neutral witnesses were examined, and no other officer supported the allegations despite being named in the FIR. The investigating officer himself did not corroborate the allegations. In light of this, a serious doubt arises regarding the prosecution's case," the judge said. The prosecution had alleged that on Sept 10, 2004, at 12.45am, Shetty and Khankar allegedly pushed aside constable Udesh Mohite, forcibly entered Kasturba Marg police station, hurled abuses, and threatened him. They reportedly entered the detection room and abused the cops and threatened police sub-inspector Radheshyam Sharma before leaving. A crucial point in the trial was the deposition of Mohite. While he admitted that one of the accused used insulting words after entering the police station, he denied lodging any complaint against them and claimed to be unaware of what transpired after they entered. Tired of too many ads? go ad free now During examination by the prosecution, he admitted that the accused pushed him and hurled abuses, and that he lodged a complaint. However, during cross-examination by the defence, he stated he could not confirm if it was intentional or accidental. He also did not specify the exact abusive words used. The judge found his testimony to be "extremely weak and unreliable". "Only after being confronted with leading questions did he admit to being pushed and abused, but those allegations are vague and unsupported. The further admissions given by him during the defence cross-examination weaken the prosecution's case even more," the judge said. Sharma deposed that he carried out the investigations and filed the chargesheet. However, he did not state that he personally witnessed the incident or corroborate the allegations in the FIR about him being insulted or intimidated. The case initially proceeded before the Mazgaon magistrate's court, which framed charges against the accused on Jan 30, 2025, and recorded prosecution witness evidence. However, the JMFC lacked jurisdiction to try the offence under Section 353 of the IPC, which was made exclusively triable by the sessions court via a state amendment. Consequently, the matter was committed to the sessions court on June 21. Fresh charges were framed against the accused by the sessions court on July 19, to which both pleaded not guilty. The prosecution opted to rely on the evidence already recorded before the JMFC, and the defence raised no objection.
Motor 1
17-06-2025
- Automotive
- Motor 1
‘It's for Weight Reduction Ofc They Use Cheap Plastic:' Why Is the Interior of This $250K Lamborghini Crunchy to the Touch?
A Lamborghini driver criticized the brand's build quality, demonstrating creaky plastic bits in its interior. Maz (@closedbymaz) posted a clip of himself to TikTok sitting in the interior of a blue Huracán where he digs his fingers into various points of the sports car's cabin. The 'insane build test' video garnered over 3.5 million views on the popular social media platform. Furthermore, it prompted a wave of different responses from other users on the application who had varying thoughts on the materials utilized in the Huracán's construction. Maz's clip begins with him focusing on the Lamborghini's steering wheel beneath a text overlay that reads, '$250k car btw.' Next, he directs his camera lens toward the Lamborghini's infotainment system. It's here that he presses into a plastic strip surrounding the vehicle's screen. It squeaks beneath the pressure before he moves his hand down to the car's shifting buttons. The covering here beneath the 'Start | Stop' ignition toggle also groans in a similar fashion. However, it's not just this plastic that flexes beneath the pressure of his hand; the armrest does too. The TikToker then directs his efforts to the air conditioning housing. This portion of the vehicle also has considerable give and wiggle as he applies some force to it. Lamborghini Seats, Too Maz's clip then transitions to him tugging on the passenger's side seatbelt. After he pulls on it, the Huracán's belt extends, but then remains floppy, not returning to its compartment, bringing the social media user's clip to a close. In a separate clip titled 'Miami Prius Build Test,' he shows off the sounds of the Huracán's buttons. The driver engages a variety of different knobs , switches, and levers, pressing them numerous times for some ASMR-style content. If the two videos are meant as a criticism of the sports car, Maz's other videos don't seem to indicate he is displeased with the vehicle. In spite of the build quality critiques and check engine light woes, Maz uploaded another video of him driving his Huracán. An on-screen caption in the clip reads, 'love this feeling,' as he rolls down a highway with the car's top down. More Lamborghini Slander Some of Maz's content appears to echo judgments of the brand's fit and finish that others online have made. This content creator, for instance, has made a series of videos demonstrating that high prices don't always equate to durability. In one of his videos, the man shows off a yellow Lamborghini Urus . As the clip progresses, he circles the car's exterior, gripping and shaking various components until they wiggle, fold, loosen, and break off. Everything from the Urus's windows to its door panels, cup holders, and dashboard plastic covers crumbles. He even manages to extricate its air conditioning vents before throwing them to the ground. At one point in the clip, he wrenches the infotainment screen from the car's dash, highlighting an Audi sticker on its back. It's an indicator that the Urus is built on the same platform as the Audi Q8 . Other pieces of the vehicle don't fare so well, either. Its rear hatch door wiggles as he pushes and pulls it in a terse, staccato movement. The wheel well covers are easily pried off and tossed to the ground with his fingers. As are the plastic engine covers under the hood and the plastic molding bits surrounding its interior seats. Commenters React Folks who responded to Maz's video had varying opinions on the Huracán's build quality. One person quipped that this reason alone is why they didn't purchase one. 'Yeah that's why I didn't buy one,' they penned. Another replied that the car's interior isn't the reason why one purchases a Lamborghini: They're built for speed. 'You [are] not supposed to press anything besides the gas pedal,' they remarked. Others highlighted that the 'cheap' plastic in Lamborghinis is utilized as a means to keep the car's heft down. 'What you want all metal?' one questioned. Someone else echoed the aforementioned sentiment, penning, 'It's for weight reduction ofc they use cheap plastic.' 'Did you expect luxury or speed,' another replied. One viewer stated that there's a distinct difference between optimizing luxury versus acceleration and handling. 'You're paying for an engine and extreme speed, not comfort. You want comfort? Go to Rolls or an S class,' they wrote. Motor1 has reached out to Maz via TikTok comment for further information. We'll be sure to update this article if we get a response. Now Trending 'Hertz Would Never:' Man Gets Pulled Over In a Rental. Then He Reaches For the Enterprise Car's Registration 'I Was Like Bait:' Woman Drives a 'Fishbowl' Car. Then She Reveals Why You Shouldn't Get the best news, reviews, columns, and more delivered straight to your inbox, daily. back Sign up For more information, read our Privacy Policy and Terms of Use . Share this Story Facebook X LinkedIn Flipboard Reddit WhatsApp E-Mail Got a tip for us? Email: tips@ Join the conversation ( )
The Star
12-06-2025
- Entertainment
- The Star
'Still Live' series in KL creates a shared space for sound and sketch
Indie folk outfit Satwo, featuring husband-and-wife duo Maz and Rafiz, is set to appear at the 'Still:Live' sunset session in Kuala Lumpur this Saturday. Photo: Maisu Blurring the lines between sight and sound, the latest edition of Ur-Mu's Still Live series pairs live painting with acoustic music for an immersive experience. Still Live – an initiative by the Ur-Mu art private museum – takes place at Boombong, The Toffee, Jalan Raja Chulan in Kuala Lumpur on June 14. Ur-Mu, which operates three distinct art gallery spaces in downtown Kuala Lumpur, will open the doors of Ur-Mu @ Toffee – its Raja Chulan outpost housing two private art collections – as part of this weekend's Still Live programme. Each ticket includes a pre-show tour led by renowned art collector and lawyer Pakhruddin 'Pakha' Sulaiman, whose 1990s Malaysian art collection fills Ur-Mu@Toffee on Level 6. Ur-Mu's 'Still Live' series blends live acoustic music with on-the-spot drawing for a uniquely immersive experience. Photo: Ur-Mu This Saturday's Still Live, a sunset session, starts at 4pm. Inspired by the art term 'still life', the series allows the audience to enjoy a live acoustic set and try their hand at live drawing. Nur Khairi Hamidi, Ur-Mu's museum coordinator, explains that while still life drawings traditionally feature inanimate objects like fruits or flowers, Still Live adds a twist – here, it's the performing musicians who become the subject. 'The idea behind Still Live is to basically combine two unique jam sessions: live acoustic performance and live drawing by the audience. We wanted to gather crowds of both fine art and music enthusiasts into one event, and break the boundaries between the two disciplines,' says Khairi. The sold-out first edition, held on Feb 22 at Ur-Mu Bukit Bintang, brought together KL-based acts Faye Faire, Note/Void, and RuoH for an intimate night of music (folk to post rock) and art. Renowned art collector Pakhruddin (centre) will be conducting a pre-show gallery tour at Ur-Mu@Toffee, where he will share insights and stories from his distinguished art collection. Photo: Pakhruddin Sulaiman 'We wanted to keep the momentum going, as we received a lot of positive feedback from those who came for the first show – for many of them, it was their first time experiencing this kind of mash-up between art and music," says Khairi. 'The musicians also had a lot of fun with the gig, because it was their first time being drawn while they performed,' he adds. The weekend's Still Live edition promises an equally compelling line-up, featuring husband-and-wife indie folk duo Satwo – joined for the first time by cellist Azrul Asyraf – alongside singer-songwriters Umar Akmal, and Syiqin Azln. For Satwo, Still Live will actually be its second art-related performance this year. Last month, the duo performed its rendition of two poems – Satu and Gurindam Apati – by Pahang-born writer and filmmaker Dr Razli Dalan at the launch of his illustrated poetry book Koleksi Puisi Puisi Sendu at the Kokopelli gallery in Petaling Jaya. Unwind with a sketch pad in hand at this relaxed evening drawing session. Photo: Ur-Mu Satwo's Rafiz Mohamed Zakaria, 44, believes that music and visual art are 'intertwined and mutually enriching.' In the live scene, Rafiz and his wife Tuan Mazlinna Tuan Abdul Malek – better known as Maz – have connected with audiences across a range of art and music events. "Since the Renaissance, music has inspired painters, opening emotional and imaginative spaces,' says Rafiz. 'Today, from album covers to performance visuals, music gives soul to form and art gives face to sound – together, they create deeper meaning," he adds. The second Still Live edition (4pm-8pm) happens at Boombong, The Toffee, Jalan Raja Chulan in Kuala Lumpur on June 14. Tickets: RM60.
The Guardian
26-04-2025
- General
- The Guardian
The dos and don'ts of good petiquette: four cardinal rules for dog owners
Across the hours of the day and the seasons of the year, Naseby Park is the place we return to, my dog and I. Surrounded by red sandstone tenements in Glasgow's West End, and roughly the size of a football pitch, this is where we first walked our four-year-old labrador Brèagha (Scots Gaelic for beautiful and she is, uncommonly so, thanks for asking). All I know about the etiquette of dog walking has been gleaned from the humans and animals who have paced its perimeter with us, and these are cardinal rules I have learned … The sine qua non of the dog walkers' code. Nobody wants to discover an abandoned turd, typically on the underside of one's shoe. Poop leavers give the rest of us dog owners a bad name. I've had animated debates with fellow walkers about whether it is ever legitimate to leave a turd. In deep undergrowth on a country walk? Beneath a jaggy bush, when retrieving it will probably require reconstructive surgery? I'm zero tolerance about poop myself, to the extent that I will pick up an unknown dog's mess if I have a spare poo bag on me. Not everyone will greet your animal with blanket delight. 'You do project your love for your dog on to the general public and that is a mistake,' acknowledges Tim, owner of Brèagha's friend Georgie, a tiny border terrier. To me Brèagha's frantic bark is a declaration of pure joy, having recently evacuated her bowels and discovered a half-eaten kebab by the bins. To a stranger, however, it could be a threat to rip their face off. A responsible dog owner must become an expert interpreter of body language and a keen risk assessor – I can precisely calculate recall time divided by fabric contact as the dog scampers through a mucky puddle and towards that woman in the pristine camel coat. There is nothing gladder than two dogs spinning nose to tail in a virtuous circle of bum-sniffing. But among primmer owners, there can be an underlying anxiety that being relaxed about this means you're up for everyone sniffing everyone's bottoms, which of course is neither practical nor desirable. Maz, owner of heart-throb labrador Otis, and I agree, we've become more laissez-faire as we've gained experience – both of our own dogs and how other dogs and humans respond to them. 'Of course dogs will snap and snarl,' she says. 'It's how they communicate. The majority of difficulties we've encountered have been with owners, not dogs, who usually know how to handle themselves, and will give dogs who are aggressive or unfriendly a wide berth.' Whenever Otis makes an apologetic attempt to hump Brèagha, for example, he gets short shrift. Plenty of those I chat to are happy for a dog to be off the lead 'so long as they come back when called'. Indeed, my cat-partial friend Lorna expresses her preference for this over acres of extendable lead lurking in the grass. Given Brèagha's genetic predisposition to greed, she is usually back at my side like a bullet for a biscuit. Maz is more militant. She believes some dog owners project their own nerves about control on to their dogs and struggle to keep them on the lead rather than learning how to manage them off. Maz also notes a certain demographic of male who likes to tell a woman how to walk her dog. 'There's an assumption that women don't know how to control a bigger dog. Men are constantly telling me Otis would be easier to control without his knackers. Which I think says more about them. But one word and he is at my side.' Cry When the Baby Cries by Becky Barnicoat is published by Jonathan Cape at £25. To support the Guardian, order your copy at Delivery charges may apply.
Business Wire
23-04-2025
- Business
- Business Wire
Boston Pharmaceuticals to Present State-of-the-Art Lecture and Poster for Once-monthly Efimosfermin Alfa at Digestive Disease Week ® 2025
BUSINESS WIRE)-- Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing efimosfermin alfa, an investigational, once-monthly FGF21 analogue for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), today announced it will present immunogenicity and biomarker analyses from its Phase 2 study, in participants with stage F2 and F3 fibrosis due to MASH. The results will be presented in a state-of-the-art lecture and poster at Digestive Disease Week (DDW) in San Diego, May 3-6, 2025. These findings further support the advancement of the efimosfermin clinical program to a Phase 3 pivotal study in 2025. 'Efimosfermin has demonstrated rapid and strong response across liver and cardiometabolic biomarkers, along with a favorable safety and tolerability profile. Its once-monthly dosing is expected to be a significant advantage for both prescribers and patients, providing confidence that efimosfermin could set a new standard in MASH treatment,' said Sophie Kornowski, CEO of Boston Pharmaceuticals. 'With our robust data, along with the commitment from our Board and a strong funding strategy, we aim to accelerate efimosfermin's development and begin enrolling patients in a Phase 3 study in F2 and F3 patients before the end of the year, followed by an F4 trial after planned discussions with regulators.' The state-of-the-art oral presentation will showcase results from the Phase 2, randomized, placebo-controlled, 24-week treatment study in participants with biopsy-confirmed F2 and F3 MASH. The study showed significant improvements in histopathology, with 45.2% (p=0.038) of participants treated with efimosfermin 300mg achieving fibrosis improvement ≥1 stage without worsening of MASH compared to 20.6% in the placebo group, and MASH resolution without worsening of fibrosis in 67.7% of participants (p=0.002) versus 29.4% at 24 weeks. Efimosfermin also demonstrated extrahepatic benefits, including positive impacts on lipids and in participants with diabetes, clinically meaningful improvements in glycemic control. In this study, efimosfermin was generally well-tolerated, with low discontinuation rates due to adverse events, and an overall low incidence of gastrointestinal side effects and injection site reactions. Data to be presented will also highlight the favorable immunogenicity profile of efimosfermin. Exploratory analyses of the phase 2 study of changes in biomarkers that identify at-risk MASH patients will be presented as a poster. These results strengthen the histopathology findings, demonstrating rapid and marked effects on biomarkers of steatosis, fibrosis, and liver injury, and supports the potential of efimosfermin as a once-monthly, disease-modifying therapeutic for the treatment of MASH. 'These analyses further support the Phase 2 study findings and provides the scientific community with the confidence to advance the development of efimosfermin as a potential therapy for patients with F2 and F3 fibrosis,' said Mazen Noureddin, M.D., lead investigator and Professor of Medicine at Houston Methodist Hospital, and Director of the Houston Research Institute. 'Based on these encouraging results, we expect to see continued progress as we evaluate findings across histology and non-invasive markers in patients with F2 and F3 MASH receiving efimosfermin treatment for up to 48 weeks.' Details of Boston Pharmaceuticals' presentations are as follows: Digestive Disease Week 2025 Oral Presentation Title: Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24 Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial Abstract Number: 723 Session: State-of-the-Art Lecture: Update on MASLD Therapies Pipeline Session Date, Time: Monday, May 5, 2025, 10:00 a.m. – 11:30 a.m. PDT Presentation Time: 11:05 a.m. – 11:20 a.m. PDT Location: 6F Presenter: Matthew Bryant, PharmD, Vice President of Medical Affairs, Boston Pharmaceuticals Expand Poster Presentation Title: Once-Monthly Efimosfermin Alfa Improves FAST and FIB-4 Composite Biomarker Scores for MASH Stage F2-F3 Fibrosis in a 24-Week Phase 2 Trial Abstract Number: Sa1504 Session: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Session Date, Time: Location: Halls C-E Presenter: Rohit Loomba, M.D., MHSc, Professor of Medicine, Chief in the Division of Gastroenterology and Hepatology, and Director of MASLD Research Center at University of California, San Diego Expand About MASH Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), is a growing global epidemic fueled by the increasing prevalence of obesity and type 2 diabetes. It is estimated that MASH affects millions of people worldwide, including 17 million in the U.S., and is expected to increase by 63% by 2030. MASH is a progressive disease staged by the degree of fibrosis (scarring) in the liver and is closely associated with multiple cardiometabolic risk factors. Left untreated, MASH could lead to liver failure, liver cancer or death. In the U.S., MASH is now a leading cause of liver transplantation. About efimosfermin alfa Boston Pharmaceuticals' lead investigational agent, efimosfermin alfa (formerly BOS-580) is a once-monthly subcutaneous injectable of a long-acting variant of human fibroblast growth factor 21 (FGF21) that regulates various metabolic pathways to decrease liver fat and ameliorate liver inflammation and damage in patients with metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The Phase 2 clinical development program of efimosfermin is continuing with an open-label extension in F2 and F3 MASH patients, providing an additional 24 weeks of treatment to assess long-term safety and efficacy up to 48 weeks. Boston Pharmaceuticals also plans to initiate a supplemental study in F4 MASH to further expand and enrich the data set for this patient population. About Boston Pharmaceuticals Boston Pharmaceuticals, a portfolio company of B-FLEXION, is a clinical-stage biopharmaceutical company that leverages an experienced and committed drug development team to advance a portfolio of highly differentiated therapies that may address important unmet medical needs in serious liver diseases, with MASH as the focus of its lead asset. The Company has significant expansion opportunities through its portfolio of promising drug development candidates that were acquired through partnerships with proven, innovative biotechnology and pharmaceutical companies. Boston Pharmaceuticals applies rigorous decision-making to advance programs to deliver differentiated medicines to patients in need of new options while creating value for all parties involved in the journey. For more information, please visit and follow us on LinkedIn. Forward-Looking Statement This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. This communication, other than statements of historic fact, are forward-looking statements. Boston Pharmaceutical's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory or prove to be commercially successful. Boston Pharmaceuticals does not undertake to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law.
